(Q34162069)
Statements
1 reference
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (English)
1 reference
Requiring an amyloid‐β1‐42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (English)
Alzheimer’s Disease Neuroimaging Initiative
1 reference
Richard E. Kennedy
Lon S. Schneider
Alzheimer’s Disease Neuroimaging Initiative
1 September 2010
1 reference
1 reference
367-377
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference